Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PTC Therapeutics has started an international pivotal trial of PTC124 in patients with Duchenne or Becker muscular dystrophy due to a nonsense mutation.
Subscribe to our email newsletter
The primary objective of this registration-directed Phase IIb trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.
In this double-blind study, patients will be randomized to receive placebo, or one of two dose levels of PTC124, three times per day. Eligible patients will be boys with nonsense-mutation-mediated Duchenne or Becker muscular dystrophy (DMD/BMD) who are at least five years of age and are able to walk at least 75 meters or approximately 80 yards in six minutes.
PTC expects to enroll a total of 165 patients at approximately 35 investigational sites; all study subjects will undergo 48 weeks of blinded treatment. Thereafter, all participants, including those who have been receiving placebo, will be eligible to enroll in an open-label PTC124 extension study.
Stuart Peltz, president and CEO of PTC Therapeutics, said: “Our future plans for PTC124 include the initiation of longer-term studies in CF, as well as additional proof-of-concept studies in other indications.”